ライフサイエンスコーパス: ME

1 ME states witnessed an annual decrease in infrainguinal

2 ME-344 is a second-generation isoflavone with unusual cy

3 ME-344 specifically bound to, and altered, HO-1 structur

4 ME-PBM achieves the long-sought goal of connecting such

5 ME-PBM is defined herein as the use of now available, ex

6 ME-SIMS analysis followed by t-distributed stochastic ne

7 ME/CFS has historically presented in outbreaks, often ha

8 MEs were acceptable by this new breakpoint, ranging from

9 evofloxacin, the CA was 72.4%, with 0 VME, 0 ME, and 16 mE (27.6%) using the 2019 CLSI disk breakpoin

10 isolates demonstrated 34.3% EA, 97.1% CA, 0% ME, and 2.9% mE, precluding the use of Etest MEV with th

11 observed for Enterobacterales (2.5% VME, 0% ME), 99.3% CA was observed for P. aeruginosa (0% VME, 0.

12 demonstrated 95.8% EA, 99.3% CA, 0% VME, 0% ME, and 0.7% mE with Enterobacterales isolates.

13 here were 4.9% VMEs for cefoxitin DD with 0% MEs, and 3.6% VMEs and 3.9% MEs for cefoxitin BMD.

14 from 75% to 90%, with 8 to 25% mE, 0 to 19% ME, and 0 to 20% VME and varied based on disk, GNB, and

15 presence and absence of the reducing agent 2-ME indicated that the predicted affinity for 25% of Cys-

16 uced in 21 rats then two concentrations of 2-ME nanoparticles were injected in right eyes of 14 rats

17 erved for Acinetobacter spp. (5.6% VME, 3.3% ME).

18 ant, >=1.0 mug/ml) led to 2.8% VMEs and 0.3% MEs.

19 uginosa isolates, 2 (6.9%) VMEs and 3 (3.3%) MEs were observed.

20 ved among the Enterobacterales, but 2 (0.4%) MEs were found.

21 of 7.1% despite 95.2% EA, 99.2% CA, and 0.5% ME compared to the reference method.

22 Cefoxitin BMD led to 4.9% VMEs and 1.6% MEs.

23 was observed for P. aeruginosa (0% VME, 0.7% ME), and 93.1% CA was observed for Acinetobacter spp. (5

24 LSI SOSA breakpoint, with 1.0% VMEs and 2.9% MEs.

25 xitin DD with 0% MEs, and 3.6% VMEs and 3.9% MEs for cefoxitin BMD.

26 trend changes in states which did not adopt ME.

27 existing evidence that genetic factors alter ME/CFS risk before concluding that most ME/CFS candidate

28 yes; 95% CI, -0.64 to -0.33; P < 0.001); and ME from NIU, -0.38 (198 eyes; 95% CI, -0.49 to -0.26; P

29 .30 (95% CI, -0.48 to -0.09; P = 0.006); and ME from NIU, -0.42 (95% CI, -0.53 to -0.29; P < 0.001).

30 ated using ABTS, ORAC 6.0 and CAA assays and ME-RBF demonstrated 26-fold, 12-fold and 2-fold higher v

31 ty eyes of 60 patients with CRVO or BRVO and ME and 40 healthy subjects underwent measurements of sup

32 0.3% under the control conditions for OJ and ME, respectively.

33 % of OTRs, and were more common in white and ME/M patients (P < .001).

34 as: the arcuate nucleus-median eminence (ARC-ME) and the paraventricular nucleus (PVN).

35 r other parameters, we conclude that the ARC-ME area (but not the PVN) is a target for sustained remi

36 0.3 ug/side) bilaterally into either the ARC-ME area or PVN of Zucker Diabetic Fatty rats, a model of

37 n action of FGF1 localized to either the ARC-ME or the PVN is capable of mimicking the sustained anti

38 ilateral microinjection of FGF1 into the ARC-ME.

39 Uveitis was active at ME diagnosis in 28 eyes (84.8%).

40 the first demonstration of a fully automated ME analysis of soil samples relevant to planetary explor

41 PBS containing SDS and beta-ME, performed significantly better than the Morinaga buf

42 Patients with bilateral ME were assigned the same treatment for both eyes.

43 on-selective channels, were also impacted by ME-344.

44 so found to be time-dependently inhibited by ME-344.

45 ystem for broader application of the Casilio-ME platforms.

46 velop a methylation editing toolbox, Casilio-ME, that enables not only RNA-guided methylcytosine edit

47 ariability in atrial biopsies from the CATCH-ME consortium atrial tissue bank, with patients stratifi

48 In epithelial cells, ME spread more efficiently, consistent with robust UL128

49 d protocol showed no differences between CFS/ME patients and healthy controls in any of the component

50 igue syndrome/Myalgic Encephalomyelitis (CFS/ME).

51 ntly be offered as a diagnostic test for CFS/ME.

52 ral blood mononuclear cells (PBMCs) from CFS/ME patients (10) and healthy controls (13).

53 Acute and chronic ME showed similar baseline and 24-week change linear cor

54 Fe(3) is observed to demonstrate a clear ME effect, whose intensity shows an unprecedented depend

55 ogy and through interaction with a clickable ME-344 compound (M2F) and subsequent proteomic analyses,

56 festations associated with IIH include CNVM, ME, SRF, VSR, chorioretinal folds, choroidal infarction,

57 en hampered so far by the lack of a coherent ME formalism.

58 orous and general ME framework, the coherent ME (CME), that overcomes both limitations.

59 For both cohorts, ME/CFS patients had an excess of individuals without a m

60 evidence that it has a heritable component, ME/CFS has not yet benefited from the advances in techno

61 For studies on converse ME effects, i.e., the magnetic response of the fibers to

62 A model was developed for the converse ME effects in the fibers and the theoretical estimates a

63 Conversely, ME expressing ADgO(GT1a) was more resistant to 14-4b.

64 Central retinal thickness (CRT), ME type, and cyst size on optical coherence tomography i

65 abolic recovery of their irradiated, damaged ME via mitochondria transfer.

66 Consequently, the VA-DES-ME procedure was successfully applied for the extraction

67 eep eutectic solvent microextraction (VA-DES-ME) procedure has been developed for the preconcentratio

68 p electrophoresis-electrochemical detection (ME-ED) platform is proposed for the first time.

69 to 0.09; P = 0.065), and eyes that developed ME during the year (incident or relapsed) experienced a

70 At baseline, those who developed ME/CFS had more physical symptoms and immune irregularit

71 dentifying three groups: those who developed ME/CFS, those who developed severe ME/CFS (meeting >1 se

72 nd immune data collected prior to developing ME/CFS..

73 d biomarkers or laboratory tests to diagnose ME/CFS.

74 he other hand, Cr(3) exhibits no discernible ME effect, which correlates well with its negligible DMI

75 Sonically disrupted ME-infected cells contained scant infectivity, suggestin

76 ll as other diet and animal covariates (DMI, ME, weight, BW(0.75), DMI/BW(0.75)).

77 uring long-term infection in the middle ear (ME), but the host cellular immune response to bacterial

78 ic low-grade inflammation of the middle ear (ME), without any signs of infection and with effusion pe

79 ns at the edge of a decaying mesoscale eddy (ME) in the Straits of Florida.

80 Macular edema (ME) is the leading cause of decreased visual acuity (VA)

81 ipsoid zone (EZ) integrity in macular edema (ME) patients.

82 nibizumab in the treatment of macular edema (ME) resulting from retinal vein occlusion (RVO).

83 ctious uveitis complicated by macular edema (ME).

84 ion disease (BRVO) cases with macular edema (ME).

85 levels of concentration and matrix effects (MEs).

86 directed at the nature of magneto-electric (ME) coupling by ferromagnetic resonance (FMR) under an e

87 Microchip electrophoresis (ME) is ideally suited for this task.

88 Mobile genetic Elements (MEs) are segments of DNA which can copy themselves and o

89 ) neurons projecting to the median eminence (ME).

90 ce of the FilmArray meningitis/encephalitis (ME) panel has received limited investigation.

91 Myalgic Encephalomyelitis (ME), also known as Chronic Fatigue Syndrome (CFS) is a d

92 , ATP citrate lyase(ACLY), and malic enzyme (ME) protein expression in LMH cells.

93 NADP-malic enzyme (ME), the most widespread C(4) decarboxylase, has increas

94 deling largely rests on the master equation (ME) approach introduced in 1975 by Hermann A.

95 Mean error (ME) was also calculated to demonstrate whether a formula

96 h 0 very major errors (VME), 4 major errors (ME) (21.1%), and 27 minor errors (mE) (46.6%) using the

97 0% very major errors (VME), 0% major errors (ME), and 0.8% minor errors (mE) with clinical and challe

98 ement (CA), minor errors (mE), major errors (ME), and very major errors (VME) were calculated for DD

99 y major errors (VMEs) and 7.1% major errors (ME).

100 major errors (VME; 3.2%) and 3 major errors (ME; 0.9%) were observed.

101 no very major errors (VMEs) or major errors (MEs) identified.

102 No additional major errors (MEs) or VMEs were found.

103 grating these mechanisms into an established ME-model, we could simulate their responses in the conte

104 Maternal exercise (ME) during pregnancy has been shown to improve metabolic

105 utcomes of surgery after Medicaid Expansion (ME) for patients with peripheral artery disease (PAD).

106 r models on each data set: mono-exponential (ME) with one discrete decay rate, bi-exponential (BE) wi

107 ale model of metabolism and gene expression (ME-model), to develop a quantitative description of the

108 of Metabolism and macromolecular Expression (ME) at genome-scale.

109 ts metabolism and macromolecular expression (ME-model).

110 ivity of sugarcane molasses ethanol extract (ME) and its fraction (ME-RBF) was evaluated using ABTS,

111 dewater orange juice (OJ) and malt extract (ME) was investigated.

112 horioretinal folds (30,68), macular exudate (ME; 20,5), choroidal neovascular membrane (CNVM; 10,15),

113 FA-ME results led to discontinuation of empirical antiviral

114 Detection of HHV-6 by FA-ME led to discontinuation of acyclovir within 12.0 h in

115 view on 25 patients positive for HHV-6 by FA-ME was performed to determine clinical presentation, com

116 Of 1,005 children tested by FA-ME, HHV-6 was detected in 25 (2.5%).

117 FilmArray Meningitis/Encephalitis panel (FA-ME; BioFire Diagnostics, Salt Lake City, UT), we aimed t

118 our institution, detection of HHV-6 using FA-ME led to faster establishment of disease etiology and o

119 The model represents the first ME-model of a Gram-positive bacterium and captures all m

120 7.4% and 4.9% for OJ and 10.7% and 6.3% for ME after 5.5 h processing under 30 V and 15 V, respectiv

121 % for OJ after 5.5 h and 14.8% and 12.8% for ME after 3.5 h under 30 V and 15 V, respectively, compar

122 goal of developing a reliable biomarker for ME/CFS and to demonstrate the utility of our platform fo

123 ng algorithms, we developed a classifier for ME/CFS patients capable of identifying new patients, req

124 normal CSF white blood cell (WBC) count for ME panel targets were 100% (195/195) for nonviral target

125 later, 55 of the 238 (23%) met criteria for ME/CFS and 157 (66%) were asymptomatic.

126 s (IM) annually, and 9-12% meet criteria for ME/CFS six months later.

127 of the nasopharyngeal niche, a reservoir for ME and upper respiratory infections.

128 stinctive microRNA expression signatures for ME/CFS through a provocation challenge is essential for

129 ndings, and treatment given specifically for ME.

130 nts of all three GHGs at the Howland Forest (ME, USA) were used to parameterize the model using a mul

131 asses ethanol extract (ME) and its fraction (ME-RBF) was evaluated using ABTS, ORAC 6.0 and CAA assay

132 ) compared with eyes that remained free from ME during the 1-year follow-up intervals, whereas eyes i

133 Patients with vision loss resulting from ME secondary to a branch or (hemi) central RVO who might

134 on processing, which is essential for future ME based devices.

135 Here we set a rigorous and general ME framework, the coherent ME (CME), that overcomes both

136 RT events, we estimate genome-wide germline ME mutation rate and selective constraint and demonstrat

137 een The Jackson Laboratory (Jax; Bar Harbor, ME, USA) and Charles River Laboratories (CR; Wilmington,

138 The CME predicts strong deviations from Haus ME, which we substantiate through an amplitude-modulated

139 Oxacillin DD yielded high ME rates (20.7 to 21.7%) using CLSI or European Committe

140 ut also more of a tendency toward hyperopia (ME +0.269 vs. -0.006 for Haigis).

141 culating microRNA expression in severely ill ME/CFS patients before and after an innovative stress ch

142 onsistent with ongoing immune alterations in ME/CFS that may illuminate the mechanism behind this dis

143 tions affected 28.1% and were more common in ME/M patients (P < .001).

144 al polyphenol and flavonoid concentration in ME-RBF are more than 10-fold higher than ME, that sugges

145 cute cases, elective procedures increased in ME states [3.9% (0.1%-7.7%), P = 0.05] along with a sign

146 and cell types that are causally involved in ME/CFS disease.

147 To investigate immune metabolism in ME/CFS, we isolated CD4+ and CD8+ T cells from 53 patien

148 n and mitochondrial DNA (mtDNA) variation in ME/CFS.

149 e investigate the role of mtDNA variation in ME/CFS.

150 We attribute the current-induced interface ME effect to modulations of the strong double-exchange i

151 Strain-coupled magnetoelectric (ME) phenomena in piezoelectric/ferromagnetic thin-film b

152 injection induced interface magnetoelectric (ME) effect.

153 he polar heterointerface on magnetoelectric (ME) coupling is not fully explored.

154 eless power method based on magnetoelectric (ME) materials enables miniature magnetically powered neu

155 nd electric (E) fields, the magnetoelectric (ME) effect, offers versatile low power consumption alter

156 tric fields to assess their magnetoelectric (ME) couplings and electric spin control.

157 Asian, 57 (3%) Middle Eastern/Mediterranean (ME/M), and 48 (2.7%) Hispanic; and 1128 (64%) male.

158 in the backgrounds of strains TR and Merlin (ME).

159 al artificial chromosome (BAC) clone Merlin (ME) expresses abundant UL128-131, is RL13 impaired, and

160 acid as a cosurfactant on the microemulsion (ME) characteristics of Thymus vulgaris essential oil (TV

161 by their bone marrow (BM) microenvironment (ME).

162 chanism-Enabled Population Balance Modeling (ME-PBM) is reported, illustrated by its application to a

163 lter ME/CFS risk before concluding that most ME/CFS candidate gene associations are not replicated by

164 hat regulation of maize (Zea mays) C(4)-NADP-ME activity is much more elaborate than previously thoug

165 propose that phosphorylation of ZmC(4)-NADP-ME at Ser419 during the first hours in the light is a ce

166 Phosphorylation of ZmC(4)-NADP-ME drastically decreases its activity as shown by the lo

167 orylation of the Ser419 residue of C(4)-NADP-ME in protein extracts of maize leaves.

168 alysis of the crystal structure of C(4)-NADP-ME indicated that Ser419 is involved in the binding of N

169 limitations of A(n) , especially among NADP-ME species.

170 No ME were observed using either CAT-1 or CAT-10.

171 li Trust, MEandYou Foundation, and Norwegian ME Association.

172 We ascertain 9 de novo MEs, 4 of which are likely causative of the patient's sy

173 The adoption of ME in 2014 was associated with significant increase in t

174 an important step towards the application of ME multiferroics.

175 roteomic analyses, showing direct binding of ME-344 with HO-1.

176 ome and either structural characteristics of ME or specific treatment strategy.

177 ti-scale analysis resolves the complexity of ME-model which hindered its practical use in proteome co

178 al. illuminate bioenergetic derangements of ME/CFS T cell subsets.

179 nd support continued clinical development of ME-344.

180 erlie the complex neuroimmune dysfunction of ME/CFS.

181 is study aimed at determining the effects of ME during pregnancy on offspring body composition and de

182 physical or mental stress, is a hallmark of ME/CFS.

183 ollow-up is needed to evaluate the impact of ME on other aspects of care and longer term outcomes of

184 tially provide us with a unique indicator of ME/CFS.

185 T were associated with a lower likelihood of ME resolution (hazard ratio [HR], 0.74; 95% CI, 0.55-1.0

186 e efficient cell-to-cell spread mechanism of ME depends on features of the intact cells such as junct

187 echanism important to the pathophysiology of ME/CFS.

188 new insights into the underlying physics of ME coupling in the model system.

189 We sought to determine predictors of ME/CFS.

190 Relapse of ME was defined as increase in macular thickness to >=240

191 at control of inflammation and resolution of ME might be visually relevant treatment targets.

192 Median time to resolution of ME was 6 months, with complete resolution in 25 eyes (75

193 Resolution of ME was defined as normalization of macular thickness on

194 included >=20% improvement and resolution of ME, best-corrected visual acuity (BCVA), and intraocular

195 pression pattern in offspring as a result of ME with the most prominent impact on Cholesterol 7 alpha

196 In contrast, spread of ME in both cell types was enhanced by Towne (TN) gO (GT4

197 iptionally repressed, cell-to-cell spread of ME was still more efficient than that of TB or TR.

198 aberrations observed in numerous studies of ME/CFS blood cells offer the opportunity to develop a di

199 dal injection of CLS-TA for the treatment of ME in a vision-threatening disorder.

200 Based on ME property, for the first time we show that MENs can di

201 ated, battery-powered, and remotely operated ME instrument coupled to laser-induced fluorescence dete

202 re found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

203 No VME or ME were observed by Etest, and 11 minor errors for cipro

204 samples were not changed by the use of AA/PA-MEs at 0.05 or 0.1% TVO.

205 The results introduce dilutable TVO:AA/PA-MEs for incorporation of TVO in aqueous systems for use

206 The antimicrobial activity of AA/PA-MEs used as a washing solution on cucumber and strawberr

207 timicrobial tests, followed closely by AA/PA-MEs.

208 Positive ME panel results were confirmed before reporting through

209 ehicle in reducing the risk of postoperative ME, with the integrated analysis showing improved BCVA a

210 acute ischemia [annual change in post vs pre-ME period (95% confidence interval): -4.3% (-7.5% to -1.

211 In the preinflamed ME environment of the Junbo mouse, neutrophils are the f

212 In this work, we present ME-Class2, a machine-learning based tool to perform inte

213 dels like GE and PD, than by discrete rates (ME and BE).

214 ing testing to pleocytic CSF samples reduced ME panel utilization by 42.7% (263 versus 459 tests perf

215 e) and CSF cryptococcal antigen or by repeat ME panel testing.

216 results were better among eyes with resolved ME, suggesting that control of inflammation and resoluti

217 Among 177 eyes with resolved ME, the cumulative percent with relapse within 7 years w

218 developed ME/CFS, those who developed severe ME/CFS (meeting >1 set of criteria) and those who were a

219 by testing patients with moderate to severe ME/CFS patients and healthy controls.

220 appear significantly associated with severe ME/CFS (p < 0.05).

221 ts and behavioral symptoms while the severe- ME/CFS group had higher levels of IL-12 and lower levels

222 Students with severe-ME/CFS were compared to students who were asymptomatic a

223 The patient with significant ME had hypertension that was treated.

224 Strikingly, ME spread far better than did TB or TR in the presence o

225 Host stromal ME recovery and donor HSPC engraftment were augmented af

226 se of the recovery of the supportive stromal ME.

227 Whether the stromal ME is damaged and how it recovers after irradiation is u

228 nsfer functional mitochondria to the stromal ME, thus improving mitochondria activity in recipient MS

229 udy assessing all individuals with suspected ME between February 2017 and April 2019 for whom the ME

230 encephalomyelitis/chronic fatigue syndrome (ME/CFS) involves severe fatigue, unrefreshing sleep, and

231 encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex chronic disease, rooted in multi-sy

232 encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease with no known cause or mech

233 encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex multisystem illness that lacks effe

234 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multisystemic disease of unkno

235 encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a highly debilitating disease with heterogene

236 encephalomyelitis/chronic fatigue syndrome (ME/CFS).

237 encephalomyelitis/chronic fatigue syndrome (ME/CFS).

238 of metabolism and macromolecular synthesis (ME-model) to gain new insights into the biology of the m

239 in ME-RBF are more than 10-fold higher than ME, that suggested antioxidant activity is correlated wi

240 and 2-fold higher values, respectively than ME.

241 Our results demonstrate that ME-Class2 will prove invaluable to interpret genome-wide

242 We previously demonstrated that ME-Class is an effective tool to understand relationship

243 We found that ME/CFS CD8+ T cells had reduced mitochondrial membrane p

244 tibodies on both cell types, indicating that ME is not simply deficient at cell-free spread but is pa

245 Overall, our data show that ME-344 inhibits HO-1 and impacts its mitochondrial trans

246 These results suggest that ME materials are an excellent candidate to enable miniat

247 The ME/CFS samples' response to the hyperosmotic stressor ob

248 ol in Fe(3) is shown to be coherent, and the ME effect exhibits complex dynamics characterized by sat

249 urrent water mass, only four days before the ME's dissipation.

250 ulated genes were correctly predicted by the ME-model, and ii) that these genes are mainly involved i

251 acid tolerance that can be simulated by the ME-model.

252 ing adenovirus with a vaccine expressing the ME-TRAP malaria antigen had no significant effect on the

253 Here, the ME coupling in BFO/LSMO heterostructures with two types

254 nfection and with effusion persisting in the ME for more than 3 months.

255 ndicate that sustained NTHi infection in the ME induces the immune suppressive response by inducing t

256 f (3 s) stimulation of TIDA terminals in the ME revealed that dopamine output is maximal at 10 Hz, wh

257 gnificantly increased dopamine levels in the ME, supporting a functional role of the transporter at t

258 ntially expressed genes accounted for in the ME-model, 80% of the upregulated genes were correctly pr

259 Outcomes included the ME panel test utilization rate, negative predictive valu

260 The introduction of the ME panel reduced the duration of acyclovir treatment fro

261 The implementation of the ME panel with restriction criteria and a selective testi

262 btained in all cases, while the study of the ME revealed the need of developing matrix-matched calibr

263 les signifying the physical footprint of the ME, such as current speed and direction.

264 enge is essential for the elucidation of the ME/CFS pathophysiology, and lead to accurate diagnoses,

265 e have implemented, validated and tested the ME-EP-JRESI sequence, demonstrating that multi-echo acqu

266 s are considered so that the approach to the ME-PBM is also extensively disproof-based.

267 en February 2017 and April 2019 for whom the ME panel was ordered.

268 Thus, ME may offer protection against offspring HFD-induced NA

269 our team has evaluated, for the first time, ME/CFS miRNomes in peripheral blood mononuclear cells (P

270 that are naturally sensitive or resistant to ME-344.

271 f pharmacologic therapeutic options to treat ME in patients with ERMs, we examine here the expression

272 At Time 2 (when they developed IM), the two ME/CFS groups tended to have more autonomic complaints a

273 d ultrasonic-assisted microextraction (IL-UA-ME) procedure has been improved for extraction of melami

274 ill patients recruited at the monographic UK ME biobank to assess, using standard operating procedure

275 Using ME-Class2 we analyze whole-genome single-base resolution

276 cient time and treatment, nearly all uveitic ME resolves, but episodes of relapse were common.

277 earched for all children treated for uveitic ME in the years 2005-2015.

278 The prognosis of pediatric uveitic ME is favorable despite its chronic course.

279 treatment in improving and resolving uveitic ME.

280 DI were superior to PTA for treating uveitic ME with modest increases in the risk of IOP elevation.

281 The strength of the voltage-ME coupling A(v) was determined from the shift in the re

282 d genes (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

283 f propylene glycol to TVO/AA or PA:T80/water MEs gave dilutable systems with particles ~59 nm in diam

284 CST, Pearson correlation coefficients were: ME from RVO, -0.35 (95% CI, -0.43 to -0.27; P < 0.001);

285 CST, Pearson correlation coefficients were: ME from RVO, -0.56 (774 eyes; 95% confidence interval [C

286 r follow-up intervals, whereas eyes in which ME did not resolve experienced no gain in vision (mean c

287 Eyes in which ME resolved gained a mean of 6.24 letters (95% CI, 4.40-

288 Wilson ME, Dobler CC, Morrow AS, et al.

289 We demonstrate that wireless ME stimulators provide therapeutic deep brain stimulatio

290 croRNA expression signatures associated with ME/CFS in response to PEM induction and reports microRNA

291 Participants (n = 1063) were diagnosed with ME from retinal vein occlusion (RVO), diabetic retinopat

292 Among 227 eyes with ME followed >=1 year, the cumulative percent of eyes wit

293 =1 year, the cumulative percent of eyes with ME resolving at any point during 7 years was 94% (95% co

294 noninferior to ranibizumab for patients with ME resulting from RVO of either subtype when receiving m

295 minority of BCVA variation in patients with ME resulting from RVO, DR, and NIU.

296 CD4+ and CD8+ T cells from 53 patients with ME/CFS and 45 healthy controls.

297 oth CD4+ and CD8+ T cells from patients with ME/CFS had reduced glycolysis at rest, whereas CD8+ T ce

298 Patients with ME/CFS had significant correlations between measures of

299 sm of specific immune cells in patients with ME/CFS.

300 d with clinical improvement in patients with ME/CFS.